MCRB

MCRB

USD

Seres Therapeutics Inc. Common Stock

$13.750-1.380 (-9.121%)

Reaalajas hind

Healthcare
Biotehnoloogia
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$15.130

Kõrge

$15.340

Madal

$13.750

Maht

0.08M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

120.4M

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

0.16M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $6.53Praegune $13.750Kõrge $24.665

Seotud uudised

GlobeNewswire

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical

Vaata rohkem
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
GlobeNewswire

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from its SER-155 Phase

Vaata rohkem
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant